
Invacare Corporation IVC
Quarterly report 2023-Q1
added 05-15-2023
Invacare Corporation General and Administrative Expenses 2011-2026 | IVC
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Invacare Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 227 M | 232 M | 236 M | 260 M | 282 M | 297 M | 304 M | 320 M | 384 M | 402 M | 415 M | 422 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 422 M | 227 M | 315 M |
Quarterly General and Administrative Expenses Invacare Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.8 M | - | 55.4 M | 58.6 M | 60.6 M | - | 56.1 M | 63.8 M | 58.8 M | - | 55.5 M | 57.4 M | 119 M | - | 63.5 M | 68.3 M | 65.2 M | - | 69.9 M | 73.8 M | 71.3 M | - | 75.9 M | 75.7 M | 72.5 M | - | 77.7 M | 78.7 M | 72.8 M | - | 77.5 M | 82.4 M | 81.2 M | - | 98.2 M | 100 M | 96.8 M | - | 97.6 M | 104 M | 103 M | - | 103 M | 104 M | 101 M | - | 104 M | 112 M | 106 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 119 M | 53.8 M | 80.5 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FONAR Corporation
FONR
|
23.5 M | $ 18.59 | -0.08 % | $ 122 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | ||
|
Globus Medical
GMED
|
1.18 B | $ 89.93 | 1.5 % | $ 12.2 B | ||
|
AdaptHealth Corp.
AHCO
|
382 M | $ 11.93 | -1.16 % | $ 1.61 B | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
16.5 M | $ 8.97 | -4.37 % | $ 254 M | ||
|
Helius Medical Technologies
HSDT
|
9.27 M | $ 1.81 | -4.74 % | $ 1.1 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
717 M | $ 9.28 | -0.32 % | $ 715 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
894 M | $ 36.52 | -0.6 % | $ 5.44 K | ||
|
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.03 | 3.75 % | $ 17.4 M | ||
|
Integer Holdings Corporation
ITGR
|
212 M | $ 85.18 | -0.53 % | $ 2.96 B | ||
|
LENSAR
LNSR
|
45.2 M | $ 5.6 | -4.92 % | $ 67 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
Medtronic PLC
MDT
|
10.8 B | $ 86.91 | 0.73 % | $ 112 B | ||
|
OrthoPediatrics Corp.
KIDS
|
120 M | $ 15.77 | -1.07 % | $ 370 M | ||
|
Myomo
MYO
|
14 M | $ 0.66 | -5.91 % | $ 27.6 M | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.42 | -1.16 % | $ 128 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
Orthofix Medical
OFIX
|
554 M | $ 11.74 | -0.25 % | $ 465 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
Align Technology
ALGN
|
1.76 B | $ 167.92 | -2.3 % | $ 12.6 B | ||
|
AxoGen
AXGN
|
44.6 M | $ 30.92 | -5.27 % | $ 1.42 B | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
Insulet Corporation
PODD
|
1.16 B | $ 202.76 | -0.36 % | $ 14.3 B | ||
|
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
6.2 M | $ 2.68 | 5.93 % | $ 7.43 M | ||
|
Smith & Nephew plc
SNN
|
2.72 B | $ 31.78 | -2.6 % | $ 23.8 B | ||
|
Stryker Corporation
SYK
|
8.65 B | $ 332.16 | -0.04 % | $ 127 B | ||
|
Butterfly Network
BFLY
|
39.8 M | $ 4.0 | -3.27 % | $ 847 M | ||
|
Tactile Systems Technology
TCMD
|
88.7 M | $ 24.1 | -1.91 % | $ 551 M | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.6 | 1.69 % | $ 37.3 M | ||
|
Tandem Diabetes Care
TNDM
|
445 M | $ 18.34 | -4.36 % | $ 1.25 B | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
43.5 M | $ 9.68 | -0.17 % | $ 347 M | ||
|
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
6.89 B | $ 61.76 | -1.33 % | $ 91.4 B | ||
|
Alphatec Holdings
ATEC
|
499 M | $ 11.07 | 0.87 % | $ 1.66 B | ||
|
Varex Imaging Corporation
VREX
|
133 M | $ 10.53 | -0.28 % | $ 436 M | ||
|
CONMED Corporation
CNMD
|
132 M | $ 34.75 | 1.97 % | $ 1.08 B | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 81.0 | -0.23 % | $ 47.4 B |